002020 京新药业
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入3,048,192-5.00%4,158,5513,998,8353,779,8463,466,550
减:营业总成本2,417,770-7.30%3,369,9443,367,0363,084,8492,841,513
    其中:营业成本1,521,964-2.99%2,080,3481,976,4881,766,1491,543,659
               财务费用(36,003)-22.69%(64,434)(53,828)(72,321)(37,581)
               资产减值损失(8,223)-8,191.71%(12,808)(21,145)(20,898)(10,271)
公允价值变动收益68-92.42%(42,367)36,77123,9527,233
投资收益16,687179.54%8,9576,44119,41648,158
    其中:对联营企业和合营企业的投资收益----(658)(6,042)(4,165)(4,252)
营业利润664,259-1.12%843,606714,059756,616698,053
利润总额664,916-1.71%843,980708,041750,316699,536
减:所得税费用83,499-12.94%124,85484,62382,49381,572
净利润581,4180.15%719,126623,418667,823617,963
减:非控股权益5,8064.67%7,1654,5205,5695,422
股东净利润575,6120.10%711,961618,898662,254612,542

市场价值指针
每股收益 (元) *0.7004.48%0.8300.7200.7700.750
每股派息 (元) *----0.3500.3000.3000.300
每股净资产 (元) *6.564-3.05%6.9336.4025.9775.321
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容